Funding
Seed · Biotech

Imperagen raises £5m seed round for enzyme engineering

PXN Ventures, IQ Capital and other participants backed computational enzyme design.

Updated Oct 16, 2026By RoundOS Funding desk

Imperagen raised £5 million in seed financing on May 21. Named participants included PXN Ventures, IQ Capital, Northern Gritstone, NPIF II–PXN Equity Finance, GMC Life Sciences Fund by PXN Ventures, Enterprise Cheshire + Warrington and Greater Manchester Combined Authority.

The company uses quantum-physics simulation and AI to engineer enzymes for pharmaceutical and industrial markets.

Funding history

Seed · This round£5M

Sources

  1. Imperagenprojectstartups.com
  2. businesswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Knowledge Work

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.

¥4.8BSeries C debt second close · Oct 23, 2026

Related